#1 Clinical Trials Search in Europe

Autologous Adipose-Derived Mesenchymal Stem Cells In Vitro Expanded

Autologous Adipose-Derived Mesenchymal Stem Cells (AD-MSCs) are at the forefront of innovative medical treatments. These cells, derived from a patient’s own fat tissue, are being studied in clinical trials for their potential to treat various conditions. This article focuses on two ongoing clinical trials investigating the use of AD-MSCs for urinary incontinence following prostate surgery and degenerative disc disease. These trials aim to evaluate the safety and effectiveness of this cutting-edge cellular therapy in addressing challenging medical conditions.

Table of Contents

What are Autologous Adipose-Derived Mesenchymal Stem Cells?

Autologous Adipose-Derived Mesenchymal Stem Cells (ADSCs), also known as AdSC-JU, are a type of stem cell therapy that uses cells from your own body fat[1][2]. These cells are special because they can develop into different types of tissues and have the potential to help repair and regenerate damaged areas in your body.

Treatment for Urinary Incontinence after Prostate Surgery

One promising application of ADSCs is in treating urinary incontinence in men who have undergone prostate surgery[1]. Urinary incontinence is when you can’t control your bladder, leading to accidental leakage of urine. This can be a distressing side effect of prostate surgery.

In this treatment:

  • ADSCs are injected into the urethral sphincter, which is the muscle that controls urine flow
  • The goal is to improve the strength and function of this muscle
  • Researchers are studying if this can reduce urine leakage and improve quality of life for patients

Treatment for Degenerative Disc Disease

Another potential use for ADSCs is in treating Degenerative Disc Disease (DDD)[2]. DDD is a condition where the discs between your spine bones (vertebrae) wear down, causing pain and other symptoms.

In this application:

  • ADSCs are injected directly into the affected spinal discs
  • The hope is that these cells can help regenerate the disc tissue
  • This could potentially reduce pain and improve disc health

How Do ADSCs Work?

ADSCs are believed to work in several ways[1][2]:

  1. They can develop into new, healthy tissue cells
  2. They release substances that promote healing and reduce inflammation
  3. They may stimulate your body’s own repair mechanisms

Current Clinical Trials

Two clinical trials are currently studying the effectiveness of ADSCs:

1. For urinary incontinence after prostate surgery[1]:

  • This is a phase I/II trial, which means it’s testing both safety and how well the treatment works
  • It’s comparing ADSC injections to a placebo (a fake treatment)
  • The main goals are to see if the treatment reduces urine leakage and if it’s safe

2. For degenerative disc disease[2]:

  • This trial is also looking at both safety and effectiveness
  • It’s comparing ADSC injections to a sham operation (a fake surgery)
  • The main goal is to see if the treatment reduces back pain and improves disc health

Who is Eligible for ADSC Treatment?

Eligibility varies depending on the specific condition being treated. Here are some general guidelines:

For urinary incontinence treatment[1]:

  • Men over 18 years old who have had prostate surgery
  • Those with moderate urinary incontinence (using 100-400g of pads per day)
  • Patients must have enough body fat for the stem cell collection

For degenerative disc disease treatment[2]:

  • Adults aged 20-60 with lower back pain
  • Those with moderate disc degeneration
  • Patients who haven’t had success with other treatments

Safety Considerations

While ADSCs show promise, it’s important to note that these treatments are still experimental[1][2]. The clinical trials are carefully monitoring for any side effects or safety issues. Some potential risks might include:

  • Infection at the injection site
  • Allergic reactions
  • Unexpected cell growth

It’s crucial to discuss all potential risks and benefits with your doctor before considering any experimental treatment.

Aspect Urinary Incontinence Trial Degenerative Disc Disease Trial
Clinical Trial Number 2023-509812-27-00 2024-514475-17-00
Main Condition Urinary incontinence after prostate surgery Degenerative disc disease
Treatment AD-MSCs injected into urethral sphincter AD-MSCs injected into intervertebral disc
Primary Objective Evaluate effectiveness and safety of AD-MSC therapy Monitor patient response and potential side effects
Key Inclusion Criteria Males over 18, stress urinary incontinence after prostatectomy Patients aged 20-60, moderate disc degeneration
Study Design Randomized, double-blind, placebo-controlled Prospective randomized double-blinded
Primary Endpoint 50% reduction in pad weight, SAE frequency Pain reduction, no unexpected events

FAQ

  • What are Autologous Adipose-Derived Mesenchymal Stem Cells? Autologous Adipose-Derived Mesenchymal Stem Cells (AD-MSCs) are stem cells taken from a person's own fat tissue. These cells have the potential to develop into different types of cells and are being studied for their ability to repair and regenerate damaged tissues.
  • What conditions are being studied using AD-MSCs in these clinical trials? The clinical trials are focusing on two main conditions: urinary incontinence in patients after prostate surgery and degenerative disc disease in the spine.
  • How are the AD-MSCs administered in these trials? For urinary incontinence, the AD-MSCs are injected within the urethral sphincter complex. In the degenerative disc disease trial, the cells are injected directly into the affected intervertebral disc.
  • What are the main objectives of these clinical trials? The main objectives are to evaluate the safety of AD-MSC therapy and to assess its effectiveness in treating the targeted conditions. This includes measuring improvements in urinary continence and reduction in back pain and disc degeneration.
  • Who can participate in these clinical trials? Eligibility varies for each trial. For the urinary incontinence trial, male patients over 18 with stress urinary incontinence after prostate surgery may be eligible. For the degenerative disc disease trial, patients aged 20-60 with moderate disc degeneration may qualify. Specific inclusion and exclusion criteria apply for each study.

Ongoing Clinical Trials on Autologous Adipose-Derived Mesenchymal Stem Cells In Vitro Expanded

  • Study on the Effectiveness and Safety of Stem Cell Therapy for Urinary Incontinence in Patients After Prostate Surgery

    Not yet recruiting

    1 1 1
    Investigated drugs:
    Poland

  • Study on Degenerative Disc Disease: Effects of Autologous Adipose-Derived Mesenchymal Stem Cells in Patients with Degenerative Disc Disease

    Not recruiting

    1 1 1
    Investigated drugs:
    Denmark

Glossary

  • Autologous Adipose-Derived Mesenchymal Stem Cells (AD-MSCs): Stem cells obtained from a person's own fat tissue, which have the potential to develop into various cell types and are being studied for their regenerative properties.
  • Urinary Incontinence: The unintentional loss of urine, often a side effect of prostate surgery in men.
  • Degenerative Disc Disease (DDD): A condition where the discs between the vertebrae of the spine deteriorate or break down, leading to pain and other symptoms.
  • Radical Prostatectomy: A surgical procedure to remove the entire prostate gland, typically performed as a treatment for prostate cancer.
  • Urethral Sphincter: A ring of muscle that controls the flow of urine from the bladder.
  • Intervertebral Disc: The cushion-like structures between the vertebrae in the spine that act as shock absorbers and allow for flexibility.
  • Clinical Trial: A research study that tests how well new medical approaches work in people, evaluating their safety and effectiveness.
  • Placebo: An inactive substance or treatment used in clinical trials as a control to compare against the active treatment being studied.
  • Randomized Double-Blind Study: A type of clinical trial where participants are randomly assigned to different treatment groups, and neither the participants nor the researchers know who is receiving which treatment.
  • Advanced Therapy Medicinal Product (ATMP): A class of innovative therapies including gene therapy, cell therapy, and tissue-engineered products.

References

  1. http://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-stem-cell-therapy-for-urinary-incontinence-in-patients-after-prostate-surgery/
  2. http://clinicaltrials.eu/trial/study-on-degenerative-disc-disease-effects-of-autologous-adipose-derived-mesenchymal-stem-cells-in-patients-with-degenerative-disc-disease/